These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12065435)

  • 21. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.
    Ok HO; Reigle LB; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Strader CD; Tota L; Wang P; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1531-4. PubMed ID: 10915043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.
    Mathvink RJ; Tolman JS; Chitty D; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Sep; 10(17):1971-3. PubMed ID: 10987429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of a novel butylated hydroxytoluene-thiazolidinone CNS antiischemic agent LY256548 in rats, mice, dogs, and monkeys.
    Ruterbories KJ; Lindstrom TD
    Drug Metab Dispos; 1990; 18(5):674-9. PubMed ID: 1981719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo pharmacological characterization of ethyl-4-[trans-4-[((2S)-2-hydroxy-3-[4-hydroxy-3[(methylsulfonyl)amino]-phenoxy]propyl) amino]cyclohexyl]benzoate hydrochloride (SAR150640), a new potent and selective human beta3-adrenoceptor agonist for the treatment of preterm labor.
    Croci T; Cecchi R; Marini P; Rouget C; Viviani N; Germain G; Guagnini F; Fradin Y; Descamps L; Pascal M; Advenier C; Breuiller-Fouché M; Leroy MJ; Bardou M
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1118-26. PubMed ID: 17351104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 3rd communication: metabolism in rats, rabbits, dogs and monkeys, and effects on hepatic drug-metabolizing enzyme activities in rats after repeated administration.
    Mukai H; Watanabe S; Morino A
    Arzneimittelforschung; 1999 Jul; 49(7):612-7. PubMed ID: 10442210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of ebrotidine in rats and dogs.
    Albet C; Pérez JA; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
    Beconi MG; Yates D; Lyons K; Matthews K; Clifton S; Mead T; Prime M; Winkler D; O'Connell C; Walter D; Toledo-Sherman L; Munoz-Sanjuan I; Dominguez C
    Drug Metab Dispos; 2012 Dec; 40(12):2297-306. PubMed ID: 22942319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of salmeterol xinafoate in laboratory animals and humans.
    Manchee GR; Barrow A; Kulkarni S; Palmer E; Oxford J; Colthup PV; Maconochie JG; Tarbit MH
    Drug Metab Dispos; 1993; 21(6):1022-8. PubMed ID: 7905380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of tiqueside (beta-tigogenin cellobioside) in dogs, rats, rabbits, and monkeys.
    Inskeep PB; Connolly AG; Cole MJ; Luther EW; Biehl ML; Marzetta CA; Savoy YE; Silber BM
    J Pharm Sci; 1995 Jan; 84(1):12-4. PubMed ID: 7714734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery.
    Nomeir AA; Morrison R; Prelusky D; Korfmacher W; Broske L; Hesk D; McNamara P; Mei H
    J Pharm Sci; 2009 Nov; 98(11):4027-38. PubMed ID: 19226636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications.
    Yeleswaram K; McLaughlin LG; Knipe JO; Schabdach D
    J Pineal Res; 1997 Jan; 22(1):45-51. PubMed ID: 9062870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of toxicity and toxicokinetics/pharmacokinetics of an alpha 1L-adrenoceptor agonist in rats and rhesus monkeys.
    Matsumaru T; Sugiura R; Sakai K; Igarashi T; Kuno T
    J Pharmacol Sci; 2005 Feb; 97(2):273-83. PubMed ID: 15699575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
    Nakamura A; Hirota T; Sugihara K; Morino A
    Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.
    Shih TL; Candelore MR; Cascieri MA; Chiu SH; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Strader CD; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 1999 May; 9(9):1251-4. PubMed ID: 10340609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
    Imanishi M; Tomishima Y; Itou S; Hamashima H; Nakajima Y; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
    J Med Chem; 2008 Mar; 51(6):1925-44. PubMed ID: 18307290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.